Related Experiment Video
Updated: Sep 19, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Early Epcoritamab Administration Revives CAR-T Cells in Relapsed/Refractory B-Cell Lymphomas
Kensuke Yanashima1, Yoshiki Furukawa1, Midori Ishii1
1Department of Hematology Juntendo University School of Medicine Tokyo Japan.
Background:
Bispecific antibodies are effective for relapsed/refractory B-cell lymphoma patients even after CAR-T therapy.
Methods:
Peripheral blood CAR-T kinetics and functional analysis in vivo were carried out pre- and post-epcoritamab infusion in B-cell lymphoma patients relapsing after CAR-T therapy.
Results:
CAR copy numbers spiked at relapse and rose again following epcoritamab administration. Expression levels of CAR-T exhaustion markers did not increase, whereas perforin and granzyme B expression increased after epcoritamab induction.
Conclusion:
Early epcoritamab administration without cytotoxic agents at relapse after CAR-T therapy revives CAR-T cell numbers and cytotoxicity, which may potentially lead to favorable clinical outcomes.
